ClinicalTrials.gg
CompletedNCT00536809Updated Dec 18, 2017Results posted

Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

A Phase 1 interventional study of lapatinib and oxaliplatin in Neoplasms, Colorectal, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-18.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.

Enrollment
156th of 183
12 · median 50
Started
2007
with 12 others
Phase 1
29 of 206
4 open now
Registered
98th of 206
by date

Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 156th largest by enrollment of the 183 interventional ones that give a count, is one of 13 that started in 2007, is one of 29 in phase 1, and was the 98th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies testing oxaliplatin in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the highest, tolerated dose level and safety of lapatinib, capecitabine and oxaliplatin in subjects with advanced cancer and to determine the clinical activity of the combination of drugs in subjects with previously untreated advanced or metastatic colorectal cancer.

03

Conditions studied

  • Neoplasms, Colorectal

Keywords

  • Metastatic Colorectal Cancer
  • oxaliplatin
  • fluoropyrimidines cancers
  • Advanced Colorectal Cancer
  • capecitabine
  • lapatinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older.
  2. A female is eligible to enter and participate in the study if she is of:

    • Non- (i.e., physiologically incapable of becoming pregnant), including any female who:
    • Has had a hysterectomy, or
    • Has had a bilateral oophorectomy (ovariectomy), or
    • Has had a bilateral tubal ligation, or
    • Is considered (defined as amenorrheic for greater than or equal to 1 year).
    • Childbearing potential, has a negative serum pregnancy test at Screening and agrees to one of the following from 2 weeks prior to enrolment and continue through the post-study visit:
    • Complete abstinence from sexual intercourse
    • Oral , either combined or progestogen alone (must use a back up method, if have taken for less than 3 cycles)
    • Injectable progestogen
    • Implants of levonorgestrel
    • Estrogenic vaginal ring
    • Percutaneous contraceptive patches
    • Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year
    • Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject
    • Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository)
  3. (ECOG) Performance Status less than or equal to 2.
  4. Provided written .
  5. greater than or equal to 8 gm/dL (5 nmol/L), if clinically stable.
  6. greater than or equal to 1,500/mm\^3 (1.5 x 109/L).
  7. Calculated (CrCl) greater than or equal to 50 mls/min.
  8. Total less than or equal to 1.25 times the institutional (ULN).
  9. (ALT) and aspartate aminotransferase (AST) less than or equal to 2 times the ULN. For subjects with liver : AST or ALT less than or equal to 5 times the ULN.
  10. greater than or equal to 50% or greater than or equal to LLN for the institution based on multiple gated acquisition scan (MUGA) or echocardiogram (ECHO).

    Specific to Phase I:

  11. Recurrent, advanced, or metastatic cancer that is known to be potentially responsive to treatment with fluoropyrimidines or oxaliplatin. Examples include gastrointestinal tumors, (ErbB2)-positive breast cancer, and lung cancers.
  12. Received less than or equal to 3 prior chemotherapy regimens without pelvic radiotherapy or less than or equal to 2 prior chemotherapy regimens if received pelvic radiotherapy.
  13. count greater than or equal to 75,000/mm\^3 (75 x 109/L).

    Specific to Phase II:

  14. -confirmed, measurable advanced or metastatic CRC previously untreated in the metastatic setting or more than 6 months post an oxaliplatin-containing therapy.
  15. Archived paraffin-embedded tumor tissue must be available for biomarker analysis.
  16. Platelet count greater than or equal to 100,000/mm\^3 (100 x 109/L).

Exclusion criteria

Exclusion Critera:

  1. Pregnant or lactating female.
  2. Prior resection of the small bowel.
  3. that require additional treatment.
  4. Medically unfit for the study as a result of the medical interview, physical exam, or screening investigations.
  5. Taking any medication on the prohibited medications list (see Section 9.2).
  6. History of drug or other allergy, which, in the opinion of the Investigator, contraindicates participation.
  7. Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to the study drugs. These include other anilinoquinazolines, such as gefitinib [Iressa], or erlotinib [Tarceva]. The subject has received treatment with any drug in the previous four weeks.
  8. Treatment with any biologic, cytotoxic, radiation , or hormonal (other than for or replacement) therapy within four weeks. Treatment with hormones with short half-lives is allowed up to 1 week prior to study treatment after consultation with GSK medical monitor.
  9. Major surgery within the previous two weeks unless in the opinion of the Investigator, the subject has recovered sufficiently to begin study treatment.
  10. Physiological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
  11. Receiving concurrent coumadin therapy. Minidose coumadin for maintenance of catheters (0.5 to 1.0 mg/day), and other anticoagulation therapy are allowed on study. Subjects receiving minidose coumadin must have (PT) or International normalized ratio (INR) and partial thromboplastin time (PTT) within 1.2 times the .
  12. History of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure.
  13. interval (QTc) greater than 450 msecs.

    Specific to Phase I:

  14. Residual chemotherapy related toxicity of greater than or equal to Grade 2 that is clinically felt likely to be exacerbated by the treatment regimen.

    Specific to Phase II (amendment written after the completion of Phase 1):

  15. Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver or stable chronic liver disease per investigator assessment.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Phase I

    Dose escalation of lapatinib along with capecitabine and oxaliplatin until the maximum tolerated dose is reached.

    Drug: oxaliplatin

  • Experimental
    Phase II

    Treatinng subjects at the maximum tolerated dose of lapatinib, capecitabine, and oxaliplatin

    Drug: lapatinib · Drug: oxaliplatin · Drug: capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response in Phase II

    The overall response is defined as the number of participants whose tumor response was classified as a complete response (CR; disappearance of all target lesions) or partial response (PR; 30% decrease in the sum of the longest diameter of target lesions) per Response Evaluation Criteria in Solid Tumors. Response was measured for participants in Phase II only. To determine response, radiographic images were taken at baseline, 8 weeks, and every 8 weeks thereafter until the participant withdrew from the study.

    Time frame: Baseline to response (up to 135 days)

Secondary outcomes

  1. Relationship Between Pretreatment Plasma TS mRNA and Pretreatment Tumor TS mRNA in Colon Tumor Biopsies.

    Exploring if there is an association with a reduction in thymidylate synthase (TS) gene expression in both plasma and tumor prior to treatment and increased sensitivity in clinical activity. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Plasma TS mRNA is collected at screening. Pre-treatment tumor sample can be archived tissue if collected within 5 years from screening; if not, tumor sample should be collected at screening.

  2. Effect of Lapatinib, Oxaliplatin, and Capecitabine on Plasma TS mRNA and the Relationship Between Plasma TS mRNA and Clinical Response

    A possible association between a reduction in thymidylate synthase (TS) gene expression and increased sensitivity in clinical activity was to be explored. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Blood samples were collected to determine TS levels at screening phase; Days 43 and 85; after every 2 cycles of treatment (+/- 3 days); and at discontinuation (if possible).

  3. Tumor-derived Biomarkers (Encoded in Protein or RNA) Associated With Clinical Outcome to Treatment

    Exploring tumor-derived biomarkers including TS, DPD, TP, EGFR (ErbB1), and additional downstream markers involved in the mechanism of action of each compound (e.g., ERCC1) and comparison to clinical response. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Pre-treatment tumor sample should have been provided for the most recent biopsy (not older than 5 years) prior to dosing. The post-treatment sample is suggested, not mandatory, and should have been collected at 43 +/-3 days.

  4. Genetic Aberrations in Somatic (Tumor) DNA Derived From the Tumor Tissue Biopsies That May Associate With Clinical Outcomes in Response to Therapy

    DNA sequencing was done to identify genetic aberrations in somatic (tumor) DNA that may associate with clinical outcomes in response to therapy. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Pre-treatment tumor sample should have been provided for the most recent biopsy (not older than 5 years) prior to dosing. The post-treatment sample is suggested, not mandatory, and should have been collected at end of Cycle 2, +/-3 days from Cycle 3.

  5. Genetic Variants in Germline (Host) DNA and Comparison to the Efficacy and Safety of the Study Drugs

    This outcome measure was conducted to investigate a possible genetic relationship to handling or response to lapatinib, oxaliplatin, and capecitabine. This measure was not analyzed due to the small number of participants who signed the optional pharmacogenetics consent.

    Time frame: Optional pharmacogenetics sample may be collected at any time during the study after consent has been obtained; however, it is recommended that it be collected at the earliest time point possible

  6. Progression-free Survival (PFS) After Lapatinib, Oxaliplatin, and Capecitabine Administered at the MTD Level of Phase II

    Both participants that entered Phase II of the study were censored for progression-free survival. Progression-free survival (PFS) is defined as the time from first dose until the first documented sign of disease progression or death due to any cause. For participants who do not progress or die, PFS was censored at the time of last radiological scan preceding the initiation of alternative anti-cancer therapy. Of the 2 participants in Phase II of the study, one discontinued due to adverse events, and the other was referred for a surgical resection.

    Time frame: Date of the first dose of study drug to the date of documented and confirmed progression by clinical, radiographic, or biochemical criteria, whichever occurred earliest, or to date of death due to any causes (up to 135 Days)

  7. Change From Baseline to Study Completion in Weight

    Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Baseline to study completion (up to 135 days)

  8. Change From Baseline to Study Completion in Heart Rate

    Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Baseline to study completion (up to 135 days)

  9. Change From Baseline to Study Completion in Blood Pressure

    Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Baseline to study completion (up to 135 days)

  10. Change From Baseline to Study Completion in Hemoglobin and Neutrophils

    Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Baseline to study completion (up to 135 days)

  11. Change From Baseline to Study Completion in White Blood Cells and Platelets

    Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Baseline to study completion (up to 135 days)

  12. Change From Baseline to Study Completion in Prothrombin Time and Partial Thromboplastin Time

    Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Baseline to study completion (up to 135 days)

  13. Change From Baseline to Study Completion in International Normalized Ratio

    Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Baseline to study completion (up to 135 days)

  14. Change From Baseline to Study Completion in Sodium, Potassium, and Calcium

    Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Baseline to study completion (up to 135 days)

  15. Change From Baseline to Study Completion in Creatinine, Total Bilirubin, and Direct Bilirubin

    Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Baseline to study completion (up to 135 days)

  16. Change From Baseline to Study Completion in Creatinine Clearance

    Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Baseline to study completion (up to 135 days)

  17. Change From Baseline to Study Completion in Aspartate Aminotransferase, Alanine Aminotranferease, and Alkaline Phosphatase

    Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

    Time frame: Baseline to study completion (up to 135 days)

07

Results

Posted Jun 9, 2010
Limitations and caveats
Phase II of the study was terminated due to lake of interest. Two participants were enrolled prior to termination. Due to the small sample size in Phase II, the data were not analyzed. The two participants' data were analyzed with Phase I data.

Participant flow

This was a Phase I/II study. Enrollment of Phase I was complete; however, Phase II of the study was terminated early due to lake of interest by sites in participating. Only 2 of the 15 planned participants were enrolled prior to termination.

Phase I (Dose-finding Phase)
Participant flow — Phase I (Dose-finding Phase)
MilestoneLapatinib/Oxaliplatin/Capecitabine
Started10
Completed10
Not completed0
Phase II
Participant flow — Phase II
MilestoneLapatinib/Oxaliplatin/Capecitabine
Started2
Completed0
Not completed2
Withdrew: Adverse event1
Withdrew: Referred for surgical resection1

Outcome measures

PrimaryOverall Response in Phase II

The overall response is defined as the number of participants whose tumor response was classified as a complete response (CR; disappearance of all target lesions) or partial response (PR; 30% decrease in the sum of the longest diameter of target lesions) per Response Evaluation Criteria in Solid Tumors. Response was measured for participants in Phase II only. To determine response, radiographic images were taken at baseline, 8 weeks, and every 8 weeks thereafter until the participant withdrew from the study.

Time frame:
Baseline to response (up to 135 days)
Reported as:
Number · participants
Overall Response in Phase II
participantsLap. 1000 mg/Oxaliplatin 130 mg/m^2/Capecitabine 1500 mg/m^2
Overall Response in Phase II2
SecondaryRelationship Between Pretreatment Plasma TS mRNA and Pretreatment Tumor TS mRNA in Colon Tumor Biopsies.

Exploring if there is an association with a reduction in thymidylate synthase (TS) gene expression in both plasma and tumor prior to treatment and increased sensitivity in clinical activity. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Plasma TS mRNA is collected at screening. Pre-treatment tumor sample can be archived tissue if collected within 5 years from screening; if not, tumor sample should be collected at screening.

No measurements were reported for this outcome.

SecondaryEffect of Lapatinib, Oxaliplatin, and Capecitabine on Plasma TS mRNA and the Relationship Between Plasma TS mRNA and Clinical Response

A possible association between a reduction in thymidylate synthase (TS) gene expression and increased sensitivity in clinical activity was to be explored. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Blood samples were collected to determine TS levels at screening phase; Days 43 and 85; after every 2 cycles of treatment (+/- 3 days); and at discontinuation (if possible).

No measurements were reported for this outcome.

SecondaryTumor-derived Biomarkers (Encoded in Protein or RNA) Associated With Clinical Outcome to Treatment

Exploring tumor-derived biomarkers including TS, DPD, TP, EGFR (ErbB1), and additional downstream markers involved in the mechanism of action of each compound (e.g., ERCC1) and comparison to clinical response. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Pre-treatment tumor sample should have been provided for the most recent biopsy (not older than 5 years) prior to dosing. The post-treatment sample is suggested, not mandatory, and should have been collected at 43 +/-3 days.

No measurements were reported for this outcome.

SecondaryGenetic Aberrations in Somatic (Tumor) DNA Derived From the Tumor Tissue Biopsies That May Associate With Clinical Outcomes in Response to Therapy

DNA sequencing was done to identify genetic aberrations in somatic (tumor) DNA that may associate with clinical outcomes in response to therapy. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Pre-treatment tumor sample should have been provided for the most recent biopsy (not older than 5 years) prior to dosing. The post-treatment sample is suggested, not mandatory, and should have been collected at end of Cycle 2, +/-3 days from Cycle 3.

No measurements were reported for this outcome.

SecondaryGenetic Variants in Germline (Host) DNA and Comparison to the Efficacy and Safety of the Study Drugs

This outcome measure was conducted to investigate a possible genetic relationship to handling or response to lapatinib, oxaliplatin, and capecitabine. This measure was not analyzed due to the small number of participants who signed the optional pharmacogenetics consent.

Time frame:
Optional pharmacogenetics sample may be collected at any time during the study after consent has been obtained; however, it is recommended that it be collected at the earliest time point possible

No measurements were reported for this outcome.

SecondaryProgression-free Survival (PFS) After Lapatinib, Oxaliplatin, and Capecitabine Administered at the MTD Level of Phase II

Both participants that entered Phase II of the study were censored for progression-free survival. Progression-free survival (PFS) is defined as the time from first dose until the first documented sign of disease progression or death due to any cause. For participants who do not progress or die, PFS was censored at the time of last radiological scan preceding the initiation of alternative anti-cancer therapy. Of the 2 participants in Phase II of the study, one discontinued due to adverse events, and the other was referred for a surgical resection.

Time frame:
Date of the first dose of study drug to the date of documented and confirmed progression by clinical, radiographic, or biochemical criteria, whichever occurred earliest, or to date of death due to any causes (up to 135 Days)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Study Completion in Weight

Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Baseline to study completion (up to 135 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Study Completion in Heart Rate

Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Baseline to study completion (up to 135 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Study Completion in Blood Pressure

Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Baseline to study completion (up to 135 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Study Completion in Hemoglobin and Neutrophils

Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Baseline to study completion (up to 135 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Study Completion in White Blood Cells and Platelets

Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Baseline to study completion (up to 135 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Study Completion in Prothrombin Time and Partial Thromboplastin Time

Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Baseline to study completion (up to 135 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Study Completion in International Normalized Ratio

Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Baseline to study completion (up to 135 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Study Completion in Sodium, Potassium, and Calcium

Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Baseline to study completion (up to 135 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Study Completion in Creatinine, Total Bilirubin, and Direct Bilirubin

Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Baseline to study completion (up to 135 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Study Completion in Creatinine Clearance

Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Baseline to study completion (up to 135 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Study Completion in Aspartate Aminotransferase, Alanine Aminotranferease, and Alkaline Phosphatase

Each on-study and follow-up laboratory parameter and vital sign was compared to the participant's baseline values to investigate what changes occurred. This analysis was not completed due to the study being closed early and the small number of participants enrolled in Phase II.

Time frame:
Baseline to study completion (up to 135 days)

No measurements were reported for this outcome.

Adverse events

Collected over Phases I and II. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lap. 1000 mg/Oxaliplatin 130 mg/m^2/Capecitabine 1500 mg/m^2—5/12 (41.7%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventLap. 1000 mg/Oxaliplatin 130 mg/m^2/Capecitabine 1500 mg/m^2
HypokalemiaMetabolism and nutrition disorders4/12
DehydrationMetabolism and nutrition disorders2/12
HyponatremiaMetabolism and nutrition disorders1/12
Laryngeal disorderRespiratory, thoracic and mediastinal disorders1/12
DiarrhoeaGastrointestinal disorders1/12
NauseaGastrointestinal disorders1/12
VomitingGastrointestinal disorders1/12
HyperbilirubinemiaHepatobiliary disorders1/12
DizzinessNervous system disorders1/12
Most frequent other events
Showing 10 of 67
Most frequent other events
EventLap. 1000 mg/Oxaliplatin 130 mg/m^2/Capecitabine 1500 mg/m^2
DiarrhoeaGastrointestinal disorders12/12
AnorexiaMetabolism and nutrition disorders10/12
NauseaGastrointestinal disorders10/12
Peripheral sensory neuropathyNervous system disorders9/12
VomitingGastrointestinal disorders9/12
FatigueGeneral disorders8/12
DizzinessNervous system disorders6/12
ConstipationGastrointestinal disorders5/12
HypokalemiaMetabolism and nutrition disorders5/12
Neuropathy peripheralNervous system disorders4/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lap. 1000 mg/Oxaliplatin 130 mg/m^2/Capecitabine 1500 mg/m^2
Mean59.9 (36 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Lap. 1000 mg/Oxaliplatin 130 mg/m^2/Capecitabine 1500 mg/m^2
Female11
Male1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lap. 1000 mg/Oxaliplatin 130 mg/m^2/Capecitabine 1500 mg/m^2
White/Caucasian/European heritage12
08

Study locations

1 site
  • GSK Investigational Site
    Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Dennie TW, Fleming RA, Bowen CJ, Dar MM, Alberti D, Oliver K, Loconte N, Mulkerin D, Holen KD. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. Clin Colorectal Cancer. 2011 Mar 1;10(1):57-62. doi: 10.3816/CCC.2011.n.008. PubMed 21609937 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2007 to primary completion in Oct 2008, 13 months.

Results were first posted in Jun 2010, 1 year 7 months after primary completion.

Of 268 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's 13 months is below that.

Counting every sponsor, half of 434 studies reached it within 48 months; a quarter within 31 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2007
First posted
Sep 28, 2007
StartActual
Sep 26, 2007
Primary completionActual
Oct 31, 2008
CompletionActual
Oct 31, 2008
Results first posted
Jun 9, 2010
Last update
Dec 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00536809
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 28, 2007
Start date
Sep 26, 2007
Primary completion
Oct 31, 2008
Completion
Oct 31, 2008
Results posted
Jun 9, 2010
Last update
Dec 18, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxaliplatin

Start the discussion